We have applied the polymerase chain reaction (PCR) technique to analyse mutations in the thymidine kinase (TK) gene of varicella-zoster virus (VZV) associated with resistance to the 5-bromovinyl (BVaraU) and 5-propynyl (PYaraU) analogues of arabinofuranosyl deoxyuridine. The results from this study allow three clear conclusions to be drawn. Firstly, the technique clearly shows that populations of VZV derived from plaque purification were truly clonal only when the plaques were initiated from cell-free virus (representing a tiny fraction of infectious virus) and plaques initiated by infected cells contained a mixture of variants. Secondly, despite the background mutations caused by errors of the Taq DNA polymerase, mutations relevant to drug resistance can easily be distinguished. The BVaraU-resistant mutant, 7-1, contained an aspartic acid to asparagine mutation at residue 18 and a single base deletion (position 65298 of the VZV DNA sequence), resulting in a frameshift and premature termination of the polypeptide chain, was found in the BVaraU-resistant mutant YSR. PYaraU-resistant virus populations contained viruses with one or more of three independent mutations, i.e. single base substitutions resulting in mutations from leucine to proline at residue 92, histidine to arginine at residue 97 and a deletion of 20bp (residues 65 135 to 65154). Finally, the technique has uncovered novel sites in the virus TK associated with drug resistance. We conclude that in vitro amplification using the PCR combined with cloning and sequencing is a relatively rapid method for identifying mutations in small virus populations even when they are not homogeneous.
Introduction
Varicella-zoster virus (VZV), the causative agent of chickenpox and shingles, encodes a 35K polypeptide with thymidine and thymidine kinase (TK) activity (Dobersen et al., 1976; Lopetegui et al., 1983) . The TK gene [open reading frame (ORF) 36] lies in the middle of the UL segment and encodes a 1.8 kb transcript (Sawyer et al., 1988; Davison & Scott, 1986) . The TK function is necessary for the activation of several antiviral nucleoside analogues such as the guanosine analogue acyclovir (ACV), currently the most effective compound in clinical use for the treatment of VZV infections. ACV is selectively phosphorylated by the virus TK and inhibits virus DNA synthesis by acting as the triphosphate. However ACV is much less active against VZV than against herpes simplex virus type 1 (HSV-1). Two promising compounds under study as possible candidates for clinical anti-VZV agents are both 5-substituted This paper was accepted for publication after the untimely death of Bob Honess, the senior author. The other authors would like to dedicate it to his memory as a colleague who is much missed. arabinofuranosyl analogues of deoxyuridine, i.e. the bromovinyl (BVaraU) and propynyl (PYaraU) analogues. BVaraU was reported to be a potent inhibitor of VZV in tissue culture with an ED50 of 0.03 ~tM by Machida et al. (1982) and has low toxicity to HEL cells (> 1200 ~tM; Suzutani et al., 1988) . PYaraU has an EDs0 for VZV of approximately 1 ~tM and negligible toxicity. Many nucleoside analogues have been described as potential anti-herpesvirus agents (De Clercq, 1988) and it is now well understood that a mechanism of selectivity for such agents involves specific phosphorylation by herpesvirus TK (Elion et al., 1977) . Mutations in the TK gene of HSV contribute significantly to antiviral drug resistance generated by exposure to ACV in the laboratory or during treatment of patients (Coen & Schaffer, 1980; Darby et al., 1981; Crumpacker et al., 1982; Erlich et al., 1989) . The analysis of such drug resistance with VZV is complex. The virus is normally cell-associated with cell-free virus representing only a very small fraction of total virus yield; thus it is difficult to ensure that an accurate picture of the virus population is obtained. Drug-resistant mutants of VZV with defective TK activity are readily isolated in tissue culture 0000-9937 © 1991 SGM S. F. Lacey and others (Biron et al., 1982; Shiraki et al., 1986 ) but relatively few have been analysed in detail, e.g. by analyses of mutated DNA sequences (Mori et al., 1988; Sawyer et al., 1988) .
Such analyses are open to the criticism of overselection of the sequenced material' through plaque purification of the virus and DNA cloning. The advent of the polymerase chain reaction (PCR) technique may allow such defects to be overcome providing it can be shown to produce reliable data on the virus population present in isolates.
We are interested in the ability of mutations in the VZV TK to contribute to resistance to antiviral drugs. In order to examine mutations in this gene conferring resistance to the two new anti-VZV drugs, BVaraU and PYaraU, we used PCR to obtain DNA sequences from TK genes encoding both wild-type and mutant enzymes. Consideration of the results of sequencing was then used to analyse each population of virus.
Methods
Virus strains. Two sources of VZV were used in this study. The wildtype strain (9883) used for selection of PYaraU-resistant virus was a clinical isolate from a patient with chickenpox who had received oral ACV at 5 mg/kg/day for 10 days ( Fig. 1 ). This isolate was passaged six times in MRC5 cells prior to making a master stock. Selection of drugresistant virus was done by three consecutive passages in CV1 cells (12 days total) under 50 ~tM-PYaraU. The PYaraU-resistant virus was handled as cell-associated material. Plaques for PCR analysis were grown on CV1 monolayers. The BVaraU-resistant variants (YSR and 7-1) from strain YS were described previously (Sakuma, 1984) . Briefly, Veto cells infected with the wild-type strain YS were treated with 10 to 20 lig/ml of IUdR, BUdR or both for 24 h, the medium containing mutagen was replaced with fresh medium and incubation continued for 48 h. BVaraU was added at 0-I to 10 ktg/ml and the monolayers were cultivated until c.p.e, was apparent. Resistant virus was cloned by plaquing with cell-free virus on HEL cells. Plaques for PCR analysis were grown on HEL monolayers.
Samples for PCR. Monolayers bearing only one or two plaques
containing about 20 infected cells were used. A Gilson pipette was used to withdraw a cell punch approximately 3 mm across containing the plaque in 50 gl of medium (i.e. <0.5 infected cells/ill). Half of the sample was transferred to a sterile Eppendorf tube which was sealed and heated to 94 °C for 5 rain. The samples were then stored at 4 °C until use. The remainder was used to inoculate a fresh monolayer in a single well of a 96-well tissue culture dish.
PCR amplification of virus material. Two p.l of the sample, calculated to correspond to less than one infected cell, was added to 100 Ill reaction mixtures in 1.5 ml Eppendorf tubes containing 50 mM-KC1, 10 mMTris-HC1 pH 8-8, 2 mM-MgCI2, 250 mM each of dGTP, dTTP, dCTP and dATP, 80 lig/ml of carageenan, each oligodeoxynucleotide (final concentration 1 p.M; see Table 1 ) and 2 units of Taq DNA polymerase (Perkin-Elmer/Cetus; Amplitaq). The reaction mixtures were overlaid with 100 ~tl of mineral oil and heated at 94 °C for 10 min in a Cambio microprocessor-controlled heating block to denature the target DNA. The reactions were then subjected to a fixed number of cycles (normally 60) comprising an initial 1 min denaturation step followed by a 1 min annealing stage at 63 °C followed by a 2 rain extension step at 72 °C. At the end of the full set of cycles, 10 ktl of each reaction mixture was analysed by agarose gel electrophoresis and visualized using ethidium bromide. The main 1181 bp product was excised from the gel, electroeluted, cleaved with EcoRI and XhoI and ligated into M 13mp 18 or mpl9 which had been treated with EcoRI and SalI. Sequencing was done using the M 13~lideoxynucleotide technology (Sanger et al., 1980) with the 17-mer universal primer (Amersham) and a series of 25-mer primers corresponding to sequences within the VZV TK fragment (Table 1) . These sequences can be identified by reference to the complete DNA sequence of VZV strain Dumas (Davison & Scott, 1986) . In this sequence the TK ORF is encoded by nucleotides 64807 to 65 829.
Expression of VZV TK in Escherichia coli. Fully sequenced TK
clones were recloned from M13 into pT7-7 (Tabor & Richardson, 1985) by PCR, employing the primers Nde and Xho (Table 1) . Ten ng of single-stranded DNA was used in a 15-cycle amplification to limit artefacts in the sequence due to Taq polymerase infidelity. The 1103 bp product was cleaved with NdeI and XhoI, gel-purified and ligated into pT7-7 linearized with NdeI and Sail. The sequences of the expression constructs were confirmed again by double-stranded plasmid DNA sequencing.
Induction and labelling of VZV TK in E. coll. Overnight cultures of E. coli transformed with the VZV TK expression constructs were diluted 1/10, incubated at 37 °C until at an optical density at 590 nm of 0.5 and then infected with an M13 derivative (mGPI-2) at an m.o.i, of at least 20. Isopropyl fl-D-tbiogalactopyranoside was added at this time to 2 mM. After 30 min further incubation, a 1 ml sample was removed to a fresh container and rifampicin added to 200 ktg/ml, followed after 10 min by 20 ~tCi of [3sS]methionine. After another 2 h of incubation, extracts for TK assays were made from the unlabelled culture by resuspension of the cells in 25 mM-Tris-HCI pH 8, 50 mM-glucose, 5' AAA ACA CTT GGC CCG AAT TCG ACT A 3' EcoRI 5' AAC ACG TAC ACT t CGA GTA TGA CAA T3' XhoI 5' CGT GCG CAT ATG TCA ACG GAT 3' NdeI 5' A GAA TTT TTA CAC CAC TTT GCA ATA 3' 5' TAT TGC AAA GTG GTG TAA AAA TTC T 3' 5' CAT GCG AAA ATC TCG GCA TTG ATG G3' 5' C CAT CAA TGC CGA GAT TTT CGC ATG 3' 5' GGG ACC AAC TTG GTA GTT TGT ACC G3' 5" C GGT ACA AAC TAC CAA GTT GGT CCC 3' 5' CGT ATT ATC GTT AGA ACA GAC ACC C 3' 5' G GGT GTC TGT TCT AAC GAT AAT ACG3' * + Indicates a primer designed to sequence (Davison & Scott, 1986) .
t Presence of a mismatch beween XhoI site (see text).
be complementary to the positive strand of the VZV the primer and the target DNA designed to create a 10 mM-EDTA, 5 mM-2-mercaptoethanol, 5 mM-ATP, 5 mM-MgC12, 5 mg/ml lysozyme and 0.5% NP40, followed by three freeze-thaw cycles. Assays were done essentially according to Dobersen et al. (1976) .
Results and Discussion

Mutations causing resistance to BVaraU
Sequence data were obtained from nine M 13 subclones of PCR products from plaques of mutant YSR and from 12 M13 subclones of PCR products from two plaques of mutant 7-1. All sequences of YSR-derived clones had a single base deletion (loss of A : T at position 65 298) and all sequences of 7-1-derived clones had a single base substitution (G:C to A:T at position 64858). In addition, all 21 subclones of these strain YS-derived genes had a silent mutation (T:A to C:G at position 64989) relative to the VZV strain Dumas DNA sequence (Davison & Scott, 1986 ) and the C:G to T:A change at position 65669 which results in the substitution of leucine for serine at residue 288 in strains other than Dumas (Sawyer et al., 1988; Davison & Scott, 1986) . The deletion in mutant YSR results in a frameshift from amino acid 164 and premature termination thereafter and satisfactorily explains the absence of TK activity in cells infected with this mutant. The base substitution in mutant 7-1 results in the substitution of asparagine for aspartic acid at residue 18 of the VZV polypeptide. An aspartic acid is present at this position within a conserved motif in eight out of 10 herpesvirus sequences (Fig. 2) , the other two viruses (Epstein-Barr virus and herpesvirus saimiri) having the alternative acidic residue, glutamic acid, at this position (Honess et al., 1989) . This conserved acidic residue forms part of the region supposed to be involved in binding ATP (Kit, 1985; see Fig. 2 ) and the substitution of asparagine would be expected to have a profound effect on enzyme activity. The previous studies on the properties of this mutant virus suggest that it retains some susceptibility to IUdR and BUdR despite resistance to BVaraU (Sakuma, 1984) and it is therefore possible that mutations in the ATP binding site can have differential effects on substrate binding or catalysis.
It is worth noting that the silent strain-specific T to C mutation at position 64989 was seen in every clone of YS origin but not in any of 9883 origin, proving that crosscontamination had not occurred in this series of experiments using the same set of PCR reagents.
Mutations causing resistance to P YaraU
The set of 17 clones derived from PYaraU-resistant plaque 1 is complex with three quasi-clonal species [one with a histidine 97 to arginine (H97R), one with a leucine 92 to proline (L92P) and a third with a 20 bp deletion (DEL; position 65135 to 65154) resulting in a frameshift and premature termination at amino acid 113] forming 70.5% of the population (Fig. 1) . Three clones (17-6%) had no observed lesion in the TK coding sequence, and (Honess et at., 1989) . The positions at which an amino acid substitution is known to confer resistance to the indicated drug are marked with a filled circle. Data are from this paper or from Sawyer et al. (1988) . The substituted amino acid is given next to the drug. The sequence shown here is that of the Dumas strain (Davison & Scott, 1986) ; both YS and 9883 strains have leucine at residue 288 and not serine as in the Dumas strain.
the remaining two clones (11.8 ~) had silent mutations at nucleotides 65091 and 65112 respectively. Similar mixed populations are seen in clones from sibling plaques 2 and 4 and the derived plaque 4.3, whereas plaque 3 and its derivative contained only a single mutation (histidine 97 to arginine). Neither the histidine at residue 97 nor the leucine at residue 92 which are altered in the only two quasi-clonal substitution mutations seen in the PYaraU-selected material are conserved at the corresponding positions in other herpesvirus TK sequences. The proline substitution at residue 92 is likely to induce quite a substantial conformational change in the protein, whereas the substitution of arginine for histidine at residue 97 may be more subtle in effect. The sequences of six clones from plaque 5 which was grown and picked under 50 BMBVaraU indicate that these two mutations also confer resistance to this compound and thus would be expected to arise at a similar frequency if BVaraU was used for selection.
Evidence that the observed mutations cause changes in TK activity
To prove formally that the H97R and the L92P point mutations had a significant effect on TK activity, we expressed clones containing solely the mutations of interest in the T7 RNA polymerase expression vector pT7-7 (Tabor & Richardson, 1985) . The TK-deficient C600 tdk strain of E. coli (Kaehler et al., 1984) was transformed with these constructs and inductions were performed by infection with mGP1-2 which expresses the T7 RNA polymerase under control of the lac promoter. On induction, the construct containing the wild-type sequence directed the synthesis of a polypeptide of apparent Mr 37000 which was specifically labelled by [35S] methionine in the presence of rifampicin. The L92P and H97R mutant polypeptides migrated as did wild-type VZV in SDS-PAGE but the L92P/ H97R double mutant ran slightly more slowly; the DEL truncation mutant gave a much smaller polypeptide and an apparent low Mr degradation product (data not shown). Significantly smaller amounts of polypeptide relative to wild-type was synthesized by the H97R mutant ( Table 2 ), suggesting that this change alters the expression of the polypeptide. This reduced level of histidine 97 to arginine enzyme was reproducible in several inductions of multiple clones.
TK assays employing [~ 4C]thymidine or [~4C]PYaraU as substrates were performed on crude E. coli extracts and the results, adjusted for the relative amounts of TK polypeptide, are given in Table 2 . The L92P and DEL single mutants and the L92P/H97R double mutant all had greatly reduced or absent TK activities using both substrates. The H97R mutant had a specific activity relative to thymidine which was comparable to or higher than that of the wild-type, but the rate at which it could phosphorylate PYaraU was much reduced. These data suggest that the H97R mutation may have reduced the affinity of the enzyme for PYaraU relative to thymidine compared to the wild-type. This effect, combined with the apparent inefficient expression of the mutant enzyme, may explain PYaraU resistance in VZV with this lesion. Clearly this is an important change in enzyme activity which deserves further examination especially since the mutant enzyme may be more efficiently expressed in infected cells.
Other observed genotypes
What is the significance of the clones with no apparent TK lesion? These could clearly represent mutations present in other genes such as the virus DNA polymerase, or that the lesions iie in the TK promoter sequences which were not studied here. It may well be, however, that a resistant virus population can harbour a minority of sensitive viruses (Honess, 1981 ). An unexpected observation was that all of the clones (11/11) from an amplification of a portion of the virus stock 4.5 were double mutants, 10 being H97R/L92P and one being L92P with the 20 bp deletion. All these mutations were seen independently in the ancestral plaque 4, and the first double mutant (L92P/DEL) was seen at 36.4% of the total in the intervening plaque 4.3. The question as to whether these represent in vitro or in vivo recombination events has not been answered. We should note that a screening procedure was inadvertently applied during the cloning procedure by excising the band corresponding to the major PCR product from the agarose gel. Any large low abundance deletions would have been eliminated by this, the 20 bp deletion having comigrated with the full-length product.
Mutations observed due to PCR error
The clonal and quasi-clonal mutations are seen against a considerable background of other mutations; 89 point substitutions and five frameshifts in 66250 residues screened, a cumulative error frequency of 1/744 (Table  3 ). The nature of these mutations suggests that nearly all are artefacts resulting from errors made by the Taq polymerase during amplification. First, there is little difference between the YS and 9883-derived material in distribution of nucleotide substitutions by type, despite their very different origins and selection pressures, suggesting that the mutations arose during amplification (Table 3) . Second, there is no bias as to position within the codons, the mutations being evenly distributed between the first, second and third nucleotides (Table 3) . Since nearly all of the sequence codes for protein one would expect that if any constraint to maintain a functional TK existed and the mutations were generated in vivo or in tissue culture (prior to exposure to any drug) then the often conservative third position in the codon would be favoured. The nature and frequency of the nonclonal mutations are broadly consistent with what is known about the fidelity of the Taq DNA polymerase. Tindall & Kunkel (1988) using an in vitro assay system obtainedanucleotidesubstitutionerrorrateof2.8 x 10 -4 substitutions per nucleotide synthesized, which agreed with the value of 2.1 x 10 -4 estimated recently (Keohavong & Thilly, 1989) by using denaturing gradient gel electrophoresis to analyse PCR products. Using the latter error rate and our observed cumulative frequency of point substitutions (1/744) we can estimate that the effective number of cycles averages 12.9. Although this is less than the 60 temperature cycles applied, the PCR reaction has been found to plateau after 25 to 40 cycles due in part to the accumulation of 'primer-dimer' sideproducts and the error rate of Taq DNA polymerase is Table 3 . * The clonal and quasi-clonal mutations (see text) are not included and some point substitutions were found just outside the ORF. t" Del, mutation resulting from a deletion; Ins, mutation resulting from an insertion event.
Frequencies of non-clonal mutations
known to depend on the reaction buffers used. The pattern of nucleotide substitutions observed in our work corresponds reasonably well, the most common (52.3 ~) in our data being A :T to G :C, whereas 59.4~ of the 32 mutations seen in other groups' data had a T to C or an A to G change. It is noticeable that most of the frameshifts arose due to an insertion or deletion in a run of bases of the same sequence, as observed previously (Dunning et al., 1988) .
Non-clonal mutations not due to PCR
It seems likely that certain of the non-clonal mutations are actually present in the virus population. For example, in the collection of clones from plaque 4.3 ( Fig. 1 and Table 3 ) the only clone which did not possess one of the quasi-clonal mutations had only a glutamine to arginine mutation at amino acid 90. This residue is highly conserved (Fig. 2) and this would be a good candidate for an inactivating point mutation. Nine of the known herpesvirus sequences have a glutamine at the equivalent position (Honess et al., 1989) , and bovine herpesvirus 1 has an arginine. A similar case could be made for the single mutation observed in a clone of plaque 1, in which the arginine at position 71 was altered to histidine. Arginine 71 is very highly conserved (Fig. 2 ) in all the herpesvirus TK sequences known.
'Cloning' VZV
Our two sets of mutants were derived by totally different techniques. The clonal nature of the BVaraU-resistant mutants shows that VZV can be cloned using cell-free virus albeit with the consequence of potentially examining only a fraction of the virus population. Cloning using plaques derived from cell-associated virus clearly does not succeed. The use of PCR allows the examination of small populations of virus for the existence of sequence variants which correlate with a resistant phenotype without the need for artefact-inducing procedures such as prolonged growth in tissue culture, virus DNA preparation and gene cloning. The use of the PCR technique has enabled us to examine widely variant isolates of VZV for mutations causing resistance to two new antiviral drugs. Having identified these mutations we are now in a position to examine their effects on the function of this enzyme which is of central importance to the action of antiherpesvirus drugs.
